Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The THOR IDE Study

NCT: NCT05916950 · RECRUITING

NCT IDNCT05916950
StatusRECRUITING
Start Date2024-10-29
Completion2027-12
SponsorPhilips Clinical & Medical Affairs Global (INDUSTRY)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to test the Thor system in adult (≥ 18 year old) patients with de novo (new, never treated) calcified lesions in infrainguinal (leg) arteries (peripheral artery disease or PAD). The main question\[s\] it aims to answer are: * Is the Thor system safe in treating these lesions * Does the Thor system work to treat these lesions Participants will: * Receive treatment with the Thor system * Have follow-up visits at Discharge, 30 days, 6 months, and 12 months

Frequently Asked Questions

What is The THOR IDE Study?

The THOR IDE Study is a clinical trial registered under NCT05916950. Current status: RECRUITING.

What is the status of NCT05916950?

The current status of NCT05916950 (The THOR IDE Study) is: RECRUITING.

When did The THOR IDE Study start?

The THOR IDE Study started on 2024-10-29.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.